Evaluation of Alpha-Amylase Inhibitory and Antidiabetic Potential of Novel 1,3,4-Oxadiazole Derivatives

Abstract

Oxadiazoles are the heterocyclic compounds containing one oxygen and two nitrogen atoms in a five membered ring possessing a diversity of useful biological effects. 134-oxadiazole is one of the most important heterocyclic moieties has wide spectrum of therapeutic activities. The activities include anticancer antimicrobial anti-inflammatory anti- HIV antitubercular antidiabetic and antifungal. The present study aims to assess the in-vitro alpha amylase inhibitory and in-vivo antidiabetic activity of some novel 134-oxadiazole derivatives. The synthesized oxadiazole derivatives SOZDs viz. SOZD1 SOZD2 SOZD3 SOZD4 and SOZD5 were evaluated for the amylase inhibition and alloxan-induced diabetic rat model. The assessment parameters are body weight fasting blood glucose FBG lipid profile enzymes and pancreas histopathology. Alphalpha-amylase inhibition assay depicted that maximum inhibition was observed at the concentration of 7000 mugml. Furthermore SOZDs treated diabetic rats show significant depletion in serum FBG urea and creatinine levels. There were statistical differences between the diabetic control and SOZD treatment groups with regard to lipid profile enzymes. Besides SOZDs reinforce the healing of alpha and beta cells of the pancreas in diabetic rats. It is evident from results that SOZD4 and SOZD5 derivatives showed a significant improvement of body weight blood parameters and lipid profile enzymes. Hence the findings of our study delineated SOZD4 and SOZD5 could be emerging as potential molecules for diabetic patients.